KRAS and adenomyosis: Importantly, the VAFs of mutations encoding oncogenic KRAS p.G12/G13 alterations (but no other mutations) were significantly enhanced in group A (mean value: 1.641%) compared with group Non-A/E (0.301%) (p = 0.008; Fig. 5b and Supplementary Data 26), suggesting that KRAS-mutated clones had expanded in NE of individuals with adenomyosis. We found that KRAS mutations were not significantly more frequent in samples from group A (p = 0.117) and group E (p = 0.297) than in those from group Non-A/E (Fig. 5a).